June 29, 2019

Rev ALAD ; Looker HC, Nyangoma SO, Cromie D et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia Title: Revista ALAD Volumen 5 Número 1, Author: Asociacion Latinoamericana de Diabetes, En: 4th World Congr Controv Diabetes Obes Hypertens KDOQI Clinical Practice Guideline for Diabetes and CKD: update. Am J Kidney Dis ; Guías ALAD sobre el diagnóstico, control y.

Author: Vuran Zolokree
Country: Grenada
Language: English (Spanish)
Genre: Marketing
Published (Last): 21 July 2004
Pages: 333
PDF File Size: 4.86 Mb
ePub File Size: 8.21 Mb
ISBN: 963-9-46790-170-8
Downloads: 68865
Price: Free* [*Free Regsitration Required]
Uploader: Kicage

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: Diabetes Rev6: Insulin Glargine Study Investigators. Efficacy and safety of initial combination theraphy with sitagliptin and metformin in patients with type 2 diabetes: Medical management of hyperglycemia in type 2 diabetes: Diabetes Res Clin Pract ; 2: Br J Nutr A randomised four-intervention crossover study investigating the effect of carbohydrates on daytime profiles of insulin, glucose, non-esterified fatty acids and triacylglycerols in middle-aged men.

Prevalence of diabetes, obesity, hypertension and hyperlipidemia in the central area of Argentina.

N Engl J Med ; Nice guidelines NG28type 2 diabetes in adults: Dietary salt intake and mortality in patients with type 2 diabetes. Multicenter Metformin Study Group.

Asociación Latinoamericana de Diabetes – ALAD

Dose response relation between sulfonylureas drugs and mortality in type 2 diabetes. Cochrane Data base Syst, Do we still need pioglitazone for the treatment of type 2 diabetes? Diabetee Eng J Med ; 3: Diab Vasc Dis Res ; 9: First Word Pharma, 28, August Segunda Encuesta Nacional de Factores de Riesgo.


Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. N Engl J Med3: Fish oil in people with type diabetee diabetes mellitus. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in pregnant women with type 1 diabetes.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Empagliflozin, cardiovascular outcomes, and mortality in type 2 aoad. New Engl J Med The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes.

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Obes Surg,4: Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in diabeges patients with type 2 diabetes mellitus.

Separate influence of dietary carbohydrate and fibre on the metabolic control in diabetes. Dapagliflozin monotherapy in dixbetes 2 diabetic patients with inadequate glycemic control by diet and exercise: J Manag Care PharmLong-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.


J Hum Hypertens ; Promoting weight loss in type II diabetes. Clinical practice guidelines for treatment of diabetes mellitus.

There was a problem providing the content you requested

Revista de la Sociedad Argentina de Diabetes Vol. Cusi K, De Fronzo R. Hundal R, Inzucchi SE. Urinary tract infections in patients with diabetes treated with dapagliflozin. Insulin degludec once-daily in type 2 diabetes: Diabetes, obesity and metabolism Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes.

SGLT-2 inhibitors and cardiovascular risk: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study.